摘要
目的观察CD3AK细胞体外杀瘤活性及其治疗中晚期原发性肝癌的效果。方法采用抗CD3单克隆抗体（CD3McAb）辅以少量rlL—2和PHA诱导外周血淋巴细胞制备CD3AK细胞。体外实验用MTT法测定其对K562、Hela—3和H7402肿瘤细胞株杀瘤活性，然后应用于临床，将140例中晚期肝癌患者随机分为三组，A组5l例（CD3AK细胞十化疗），B组45例（单纯化疗），C组44例（单用CD3AK细胞治疗）。结果CD3AK细胞体外对K562、Hela－3和H7402细胞株杀瘤率分别为78．54％、34．09％和64．37％，抗肿瘤效应的最佳时期在培养的第7～10天之间；临床治疗部分缓解率（PR）A、B、C组分别为45．1％、17．7％和20．5％，A、B两组比较有显著性差异（P＜0．o1）。结论CD3AK细胞是继LAK细胞后又一为有效的杀瘤细胞，临床应用安全可靠、有效，在中晚期肝癌辅助治疗中有着良好的应用价值，合理结合其它疗法可增强疗效。
Objective To observe CD3AK cells (anti-CD3 antibody activated killer cell) anti-tumor activity in vitro and the therapeutic effectiveness in treating advanced primary cancer (PLC).Method: The CD3AK cells were made of peripheral blood lymphocytes which were induced withtrace anti-CD3 monoclonal antibody plus rIL--2 and PHA and its anti-tumor activity in vitro againstK562, Hela-3 and H7402 was detected by MTT method, then clinical trial were performed on 140 pa-tients with PLC which were divided into Group A (CD3AK + chemotherapy, 51 cases), Group B(chemotherapy alone, 45 cases) and GroupC (CD3AK cells alone, 44 cases). Results: The anti-tu-mor activity in vitro of CD3AK against K562, Hela-3 and H7402 were 78. 54%, 34. 09% and 64.37% respecively. The period of the highest anti-tumor activity was in culture for 7-10 days. Therates of remission in clinical trial were 45. l% in Group A, 17. 7% in Group B (in compare withGroup A P＜O. o1). Conclusions: The result Suggested that the CD3AK cell is another more efficientkiller cell after LAK cell and there was effectiveness and safety in its clinical application. It has anexcellent applied value in the supplementary treatment for advanced PLC and it can enhance thera-peutic effectiveness in combination with other therapies.
出处
《中国肿瘤临床与康复》
1998年第5期6-8,共3页
Chinese Journal of Clinical Oncology and Rehabilitation
基金
广西自然科学基金
